Orladeyo Now Available for Hereditary Angioedema
The oral, once-daily treatment will be shipped to patients with a prescription by specialty pharmacy Optime Care, Inc.
Hereditary Angioedema
FDA Approves Orladeyo to Prevent Hereditary Angioedema Attacks
Orladeyo works by binding to plasma kallikrein and inhibiting its proteolytic activity.
Lanadelumab Markedly Reduces Hereditary Angioedema Attacks Over 30-Month Period
Lanadelumab was effective for reducing hereditary angioedema attacks at up to 30 weeks of treatment, suggesting the monoclonal antibody is associated with sustained long-term efficacy.
Berotralstat Improves Quality of Life in Hereditary Angioedema
Patients with hereditary angioedema taking berotralstat prophylactically had improved quality of life.
Haegarda Approved for Pediatric Hereditary Angioedema
The expanded approval was based on data from the pivotal phase 3 COMPACT study and the COMPACT open-label extension study.
Berotralstat NDA for Hereditary Angioedema Prophylaxis Submitted to FDA
The New Drug Application (NDA) for berotralstat (BCX7353; BioCryst) for the prevention of hereditary angioedema (HAE) attacks has been submitted to the Food and Drug Administration.
Long-Term Data Show Lanadelumab Effective in Preventing HAE Attacks
This article is part of MPR‘s coverage of the ACAAI 2019 meeting, taking place in Houston, TX. Our staff will report on medical research related to allergies, asthma, and more conducted by experts in the field. Check back regularly for more news from ACAAI 2019. Data from the open-label extension (OLE) portion of the phase…
BCX7353 Reduced Hereditary Angioedema Attacks Over 24 Week
The oral plasma kallikrein inhibitor, BCX7353, reduced hereditary angioedema attacks during a 24-week treatment period.
Oral Plasma Kallikrein Inhibitor Prevents HAE Attacks in Phase 3 Trial
Results from a phase 3 trial evaluating BCX7353 (BioCryst), an investigational therapy for hereditary angioedema (HAE), showed that the oral plasma kallikrein inhibitor significantly reduced the rate of HAE attacks, the primary endpoint of the study.
Lanadelumab Does Not Increase Cardiovascular Risk in Hereditary Angioedema
This article is part of MPR‘s coverage of the American Academy of Allergy, Asthma & Immunology annual meeting, taking place in San Francisco, California. Our staff will report on medical research related to asthma, allergy, and other respiratory conditions, conducted by experts in the field. Check back regularly for more news from AAAAI 2019. Researchers sought to examine…
